Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders
AUTOR(ES)
Málaga, Diana Rojas
FONTE
Genet. Mol. Biol.
DATA DE PUBLICAÇÃO
11/04/2019
RESUMO
Abstract Lysosomal storage disorders (LSDs) constitute a heterogeneous group of approximately 50 genetic disorders. LSDs diagnosis is challenging due to variability in phenotype penetrance, similar clinical manifestations, and a high allelic heterogeneity. A powerful tool for the diagnosis of the disease could reduce the “diagnostic odyssey” for affected families, leading to an appropriate genetic counseling and a better outcome for current therapies, since enzyme replacement therapies have been approved in Brazil for Gaucher, Fabry, and Pompe diseases, and are under development for Niemann-Pick Type B. However, application of next-generation sequencing (NGS) technology in the clinical diagnostic setting requires a previous validation phase. Here, we assessed the application of this technology as a fast, accurate, and cost-effective method to determine genetic diagnosis in selected LSDs. We have designed two panels for testing simultaneously 11 genes known to harbor casual mutations of LSDs. A cohort of 58 patients was used to validate those two panels, and the clinical utility of these gene panels was tested in four novel cases. We report the assessment of a NGS approach as a new tool in the diagnosis of LSDs in our service.
Documentos Relacionados
- The Role of Next-Generation Sequencing in the Diagnosis of Lysosomal Storage Disorders
- Application of Next-generation Sequencing in Clinical Molecular Diagnostics
- Glycogen Storage Diseases: Next-Generation Medicine
- Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era
- Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?